Newron Pharmaceuticals SpA

Newron Pharmaceuticals has a negative equity position of EUR -11.14 million, indicating a significant financial leverage burden. The company's liquidity position is characterized by a current ratio of 0.76, suggesting that it has less than one euro in current assets for every euro of current liabilities. The debt-to-equity ratio is -3.43, which is highly unusual and indicates that the company's liabilities exceed its equity by a large margin.

Profitability metrics show a mixed picture. The company reported a gross profit of EUR 17.02 million, but this was offset by an operating loss of EUR -4.70 million and a net loss of EUR -13.24 million. The return on equity is 1.189, which is positive but misleading due to the negative equity base. The return on assets is -0.3305, indicating that the company is not generating a return on its asset base.

Newron Pharmaceuticals' revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue of EUR 19.13 million is derived from its core operations in healthcare diagnostics, but there is no information on the geographic distribution of this revenue.

The company's growth trajectory is uncertain. While it has a positive operating cash flow of EUR 32.35 million, this is largely offset by a negative free cash flow of EUR -13.12 million. The capital expenditure of EUR -48,000 is minimal, suggesting limited investment in new projects or expansion.

Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations without external financing. The dilution risk is low, but the company's negative equity position could necessitate future equity raises, which may dilute existing shareholders.

Recent events include analyst estimates that suggest a mean price target of EUR 45.25 and a median price target of EUR 41.50. The mean recommendation is 2.00, indicating a "buy" rating, with four "buy" ratings and no "strong buy" or "hold" ratings.